论文部分内容阅读
非小细胞肺癌(NSCLC)联合化疗的研究资料较少,文献报道大都认为此类肿瘤对化疗敏感性较低而不予重视。晚近,科学家们通过一系列药物的实验研究,观察到某些药物对NSCLC 有一定疗效。本文对近二年来晚期NSCLC 患者采用联合化疗的各种方案及其疗效进行综述,供临床参考。【化疗方案及疗效】1.长春花碱酰胺和顺铂(VDS-DDP)方案:业已证明VDS 和DDP 对NSCLC 均为单项敏感药物。Fuks 等报告,以上二药联合应用时可增加对NSCLC 的敏感性(11例中有效率44%),并对延长存活期有统计学意义。在诱导化疗中用VDS 3mg/m~2每
There are few studies on non-small cell lung cancer (NSCLC) combined with chemotherapy. The literature reports that most of these tumors do not pay attention to chemotherapy sensitivity. Lately, scientists have conducted experimental studies on a series of drugs and observed that certain drugs have a certain effect on NSCLC. This article reviews the various strategies and efficacy of the combination chemotherapy for advanced NSCLC patients in the last two years for clinical reference. 【Chemotherapy options and efficacy】 1. Vinblastine and cisplatin (VDS-DDP) protocol: VDS and DDP have been shown to be single sensitive drugs for NSCLC. Fuks et al. reported that the combination of the above two drugs may increase the sensitivity to NSCLC (44% in 11 cases) and have a statistically significant prolongation of survival. VDS 3mg/m~2 per use in induction chemotherapy